Recent Securities Litigations

Talis Biomedical Corporation Common Stock (NASDAQ: TLIS)

Company Name:Talis Biomedical Corporation Common Stock
Stock Symbol:NASDAQ: TLIS
Class Period Start:02/12/2021
Class Period End (inclusive):01/07/2022

The Complaint action alleges that the Registration Statement was false and misleading and omitted to state material adverse facts. Specifically, the Complaint alleges Defendants failed to disclose to investors: (1) that the comparator assay in the primary study lacked sufficient sensitivity to support Talis’s EUA application for Talis One COVID-19 test; (2) that, as a result, Talis was reasonably likely to experience delays in obtaining regulatory approval for the Talis One COVID-19 test; (3) that, as a result, the Company’s commercialization timeline would be significantly delayed; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.